Serum Bilirubin Levels and Cardiovascular Disease Risk: A Janus Bifrons?

Advances in Clinical Chemistry

Volumn 50, Issue , 2010, Pages 47-63

  Franchini, Massimo ^a   Targher, Giovanni ^b   Lippi, Giuseppe ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BIOLOGICAL MARKER;

BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; HUMAN; HYPERBILIRUBINEMIA; METABOLISM; REVIEW; RISK FACTOR;

BILIRUBIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; HYPERBILIRUBINEMIA; RISK FACTORS;

EID: 77954047398     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(10)50003-9     Document Type: Chapter

References (53)

1. [1] Vítek, L., Ostrow, J.D., Bilirubin chemistry and metabolism; harmful and protective aspects. Curr. Pharm. Des. 15 (2009), 2869–2883.
2. [2] Vítek, L., Schwertner, H.A., The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem. 43 (2007), 1–57.
3. [3] Thaler, M., Luppa, P.B., Schlebusch, H., Bilirubin measurement—an updated survey. J. Lab. Med. 32 (2008), 1–9.
4. [4] Westwood, A., The analysis of bilirubin in serum. Ann. Clin. Biochem. 28 (1991), 119–130.
5. [5] Doumas, B.T., Wu, T.W., The measurement of bilirubin fractions in serum. Crit. Rev. Clin. Lab. Sci. 28 (1991), 415–445.
6. [6] Doumas, B.T., Kwok-Cheung, P.P., Perry, B.W., Jendrzejczak, B., McComb, R.B., Schaffer, R., et al. Candidate reference method for determination of total bilirubin in serum: development and validation. Clin. Chem. 31 (1985), 1779–1789.
7. [7] National Committee for Clinical Laboratory Standards (NCCLS), Reports on analyte reference summaries of the National Reference System for Clinical Laboratory, NRSCL, RS-6-A, Villanova, NCCLS 1989.
8. [8] Jendrassik, L., Grof, P., Vereinfachte photometrische Methode zur Bestimmung des Bilirubins. Biochem. Z. 297 (1938), 81–89.
9. [9] Watson, D., Rogers, J.A., A study of six representative methods of plasma bilirubin analysis. J. Clin. Pathol. 14 (1961), 271–278.
10. [10] Nakayama, K., Differences between enzymatic and diazo methods for measuring direct bilirubin. Eur. J. Clin. Chem. Clin. Biochem. 33 (1995), 513–517.
11. [11] Kirk, J.M., Neonatal jaundice: a critical review of the role and practice of bilirubin analysis. Ann. Clin. Biochem. 45 (2008), 452–462.
12. [12] Tietz, N.W., Clinical Guide to Laboratory Tests. second ed., 1990, WB Saunders, Philadelphia, PA.
13. [13] Wolkoff, A.W., The hyperbilirubinemias. Fauci, A.S., Braunwald, E., Kasper, D.L., Hauser, S.L., Longo, D.L., Jameson, J.L., Loscalzo, J., (eds.) Harrison's. Principles of Internal Medicine, 17th ed., 2008, McGraw-Hill, New York.
14. [14] Schwertner, H.A., Jackson, W.G., Tolan, G., Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40 (1994), 18–23.
15. [15] Hopkins, P.N., Wu, L.L., Hunt, S.C., James, B.C., Vincent, G.M., Williams, R.R., Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 16 (1996), 250–255.
16. [16] Perlstein, T.S., Pande, R.L., Beckman, J.A., Creager, M.A., Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 166–172.
17. [17] Perlstein, T.S., Pande, R.L., Creager, M.A., Weuve, J., Beckman, J.A., Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999–2004. Am. J. Med. 121 (2008), 781–788.
18. [18] Erdogan, D., Gullu, H., Yildirim, E., Tok, D., Kirbas, I., Ciftci, O., et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184 (2006), 431–437.
19. [19] Gullu, H., Erdogan, D., Tok, D., Topcu, S., Caliskan, M., Ulus, T., et al. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 2289–2294.
20. [20] Breimer, L.H., Wannamethee, G., Ebrahim, S., Shaper, A.G., Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin. Chem. 41 (1995), 1504–1508.
21. [21] Djoussé, L., Levy, D., Cupples, L.A., Evans, J.C., D'Agostino, R.B., Ellison, R.C., Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am. J. Cardiol. 87 (2001), 1196–1200.
22. [22] Fulks, M., Stout, R.L., Dolan, V.F., Mortality associated with bilirubin levels in insurance applicants. J. Insur. Med. 41 (2009), 49–53.
23. [23] Temme, E.H., Zhang, J., Schouten, E.G., Kesteloot, H., Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12 (2001), 887–894.
24. [24] Kimm, H., Yun, J.E., Jo, J., Jee, S.H., Low serum bilirubin level as an independent predictor of stroke incidence. A prospective study in Korean men and women. Stroke, 2009.
25. [25] Lin, J.P., O'Donnell, C.J., Schwaiger, J.P., Cupples, L.A., Lingenhel, A., Hunt, S.C., et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114 (2006), 1476–1481.
26. [26] Lin, J.P., Schwaiger, J.P., Cupples, L.A., O'Donnell, C.J., Zheng, G., Schoenborn, V., et al. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels—the Framingham Heart Study. Atherosclerosis 206 (2009), 228–233.
27. [27] Johnson, A.D., Kavousi, M., Smith, A.V., Chen, M.H., Dehghan, A., Aspelund, T., et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum. Mol. Genet. 18 (2009), 2700–2710.
28. [28] Vítek, L., Jirsa, M., Brodanová, M., Kalab, M., Marecek, Z., Danzig, V., et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160 (2002), 449–456.
29. [29] Stocker, R., Yamamoto, Y., McDonagh, A.F., Glazer, A.N., Ames, B.N., Bilirubin is an antioxidant of possible physiological importance. Science 235 (1987), 1043–1046.
30. [30] McCarty, M.F., “Iatrogenic Gilbert syndrome”—a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med. Hypotheses 69 (2007), 974–994.
31. [31] Neuzil, J., Stocker, R., Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J. Biol. Chem. 269 (1994), 16712–16719.
32. [32] Wu, T.W., Fung, K.P., Yang, C.C., Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 54 (1994), P477–P481.
33. [33] Wu, T.W., Fung, K.P., Wu, J., Yang, C.C., Weisel, R.D., Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem. Pharmacol. 51 (1996), 859–862.
34. [34] Yesilova, Z., Serdar, M., Ercin, C.N., Gunay, A., Kilciler, G., Hasimi, A., et al. Decreased oxidation susceptibility of plasma low density lipoproteins in patients with Gilbert's syndrome. J. Gastroenterol. Hepatol. 23 (2008), 1556–1560.
35. [35] Bulmer, A.C., Blanchfield, J.T., Toth, I., Fassett, R.G., Coombes, J.S., Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 199 (2008), 390–396.
36. [36] Spranger, T., Finckh, B., Fingerhut, R., Kohlschütter, A., Beisiegel, U., Kontush, A., How different constituents of human plasma and low density lipoprotein determine plasma oxidizability by copper. Chem. Phys. Lipids 91 (1998), 39–52.
37. [37] Wiedemann, M., Kontush, A., Finckh, B., Hellwege, H.H., Kohlschütter, A., Neonatal blood plasma is less susceptible to oxidation than adult plasma owing to its higher content of bilirubin and lower content of oxidizable Fatty acids. Pediatr. Res. 53 (2003), 843–849.
38. [38] Minetti, M., Mallozzi, C., Di Stasi, A.M., Pietraforte, D., Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch. Biochem. Biophys. 352 (1998), 165–174.
39. [39] Ostrow, J.D., Tiribelli, C., Bilirubin, a curse and a boon. Gut 52 (2003), 1668–1670.
40. [40] Granato, A., Gores, G., Vilei, M.T., Tolando, R., Ferraresso, C., Muraca, M., Bilirubin inhibits bile acid induced apoptosis in rat hepatocytes. Gut 52 (2003), 1774–1778.
41. [41] Stocker, R., Peterhans, E., Synergistic interaction between vitamin E and the bile pigments bilirubin and biliverdin. Biochim. Biophys. Acta 1002 (1989), 238–244.
42. [42] Stocker, R., Glazer, A.N., Ames, B.N., Antioxidant activity of albumin-bound bilirubin. Proc. Natl. Acad. Sci. USA 84 (1987), 5918–5922.
43. [43] Yamashita, K., McDaid, J., Ollinger, R., Tsui, T.Y., Berberat, P.O., Usheva, A., et al. Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts. FASEB J. 18 (2004), 765–767.
44. [44] Arriaga, S.M., Mottino, A.D., Almará, A.M., Inhibitory effect of bilirubin on complement-mediated hemolysis. Biochem. Biophys. Acta 1473 (1999), 329–336.
45. [45] Basiglio, C.L., Arriaga, S.M., Pelusa, H.F., Almará, A.M., Roma, M.G., Mottino, A.D., Protective effects of unconjugated bilirubin on complement-mediated hepatocytolysis. Biochem. Biophys. Acta 1770 (2007), 1003–1010.
46. [46] Arriaga, S.M., Basiglio, C.L., Mottino, A.D., Almará, A.M., Unconjugated bilirubin inhibits C1 esterase activity. Clin. Biochem. 42 (2009), 919–921.
47. [47] Ollinger, R., Wang, H., Yamashita, K., Wegiel, B., Thomas, M., Margreiter, R., et al. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid. Redox Signal. 9 (2007), 2175–2185.
48. [48] Dore, S., Goto, S., Sampei, K., Blackshaw, S., Hester, L.D., Ingi, T., et al. Heme oxygenase-2 acts to prevent neuronal death in brain cultures and following transient cerebral ischemia. Neuroscience 99 (2000), 587–592.
49. [49] Dore, S., Sampei, K., Goto, S., Alkayed, N.J., Guastella, D., Blackshaw, S., et al. Heme oxygenase-2 is neuroprotective in cerebral ischemia. Mol. Med. 5 (1999), 656–663.
50. [50] Sedlak, T.W., Saleh, M., Higginson, D.S., Paul, B.D., Juluri, K.R., Snyder, S.H., Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc. Natl. Acad. Sci. USA 106 (2009), 5171–5176.
51. [51] Nath, K.A., Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int. 70 (2006), 432–443.
52. [52] Bulmer, A.C., Ried, K., Blanchfield, J.T., Wagner, K.H., The anti-mutagenic properties of bile pigments. Mutat. Res. 658 (2008), 28–41.
53. [53] Lippi, G., Montagnana, M., Franchini, M., Favaloro, E.J., Targher, G., The paradoxical relationship between serum uric acid and cardiovascular disease. Clin. Chim. Acta 392 (2008), 1–7.